The p53 tumor-suppressor protein is induced in response to various types of oncogenic stress, functioning to arrest cell proliferation and induce cell death. Numerous mechanisms exist to control p53, with a key role for the RING-domain proteins MDM2 and MDMX. In mice, deletion of either MDM2 or MDMX results in early embryonic lethality due to uncontrolled p53 activation [1] [2] [3] [4] [5] [6] [7] .
a r t i c l e s
The p53 tumor-suppressor protein is induced in response to various types of oncogenic stress, functioning to arrest cell proliferation and induce cell death. Numerous mechanisms exist to control p53, with a key role for the RING-domain proteins MDM2 and MDMX. In mice, deletion of either MDM2 or MDMX results in early embryonic lethality due to uncontrolled p53 activation [1] [2] [3] [4] [5] [6] [7] .
In healthy, unstressed cells, MDM2 is localized primarily in the nucleus where it binds and inhibits p53, partly by ubiquitinating p53 and targeting it for proteasomal degradation 8 . The MDM2 RING domain is necessary for the protein's ubiquitin ligase (E3) activity and for its dimerization with itself or with the RING domain of MDMX. Although MDMX can homodimerize at micromolar concentration in vitro 9 , in cells MDMX does not homodimerize and possesses no intrinsic E3 activity [10] [11] [12] [13] . However, MDM2 and MDMX form an active E3 heterodimer, and some studies suggest that this complex is the physiologically relevant ligase. MDM2's E3 activity also contributes to transcriptional repression by ubiquitinating histones within promoters 14 . Furthermore, interactions between MDM2 and p53 can directly inhibit the transcription-factor function of p53 by altering interactions with other components of the transcriptional machinery [15] [16] [17] .
Mutations that prevent MDM2 RING domain homo-or heterodimerization lead to the loss of E3 activity and failure to restrain p53 function 6, 7, 18 . The C-terminal tail of MDM2 is also important for E3 activity, although this function can be provided by MDMX in vitro 19, 20 . Interestingly, in vivo, an MDM2-tail mutant controlled p53 activity sufficiently to allow normal development, despite accumulation of p53 above basal levels in some tissues 21 . These results suggest that MDM2 may be able to control p53 through degradationindependent mechanisms.
The induction of p53 in response to stress is accompanied by the inhibition of MDM2, leading to the stabilization of transcriptionally active p53. Defects in the ability to inactivate MDM2 are frequently seen in cancers that retain wild-type p53, in which small-molecule inhibitors of MDM2 may have a therapeutic benefit 22 . Several drugs that target the binding of p53 to MDM2 have been developed [23] [24] [25] and show excellent specificity in stabilizing and activating p53. However, on-target toxicities, including thrombocytopenia and neutropenia, appear to limit the efficacy and utility of these compounds 26, 27 .
Previous studies have shown that the RING domain of MDM2 functions to recruit the E2 ubiquitin-conjugating enzyme thioesterified with ubiquitin (E2~Ub; ~ indicates thioester bond) and facilitate ubiquitination 28, 29 . We have solved the crystal structure of the MDM2-MDMX RING-domain heterodimer bound to E2 (UbcH5B) covalently linked to ubiquitin (UbcH5B-Ub; C terminus of Ub is covalently linked to UbcH5B's catalytic cysteine) and generated MDM2 mutants that retain RING-domain integrity but do not interact with UbcH5B-Ub. While these mutants are unable to ubiquitinate and degrade p53, they retain the ability to limit p53 activity.
RESULTS

Structure of MDM2-MDMX RING domain bound to UbcH5B-Ub
To understand how the MDM2 RING domain binds and activates E2~Ub for catalysis, we assembled both an MDM2 RING homodimer (MDM2 RH ; MDM2 428-C) and an MDM2-MDMX RING heterodimer (MDM2 R -MDMX R ; MDM2 428-C and MDMX 427-C) in complex with UbcH5B-Ub for crystallization. The UbcH5B-Ub complex was obtained by mutating UbcH5B's C85 to a lysine to form an isopeptide bond with the C-terminal glycine of Ub 30, 31 . Only the and the hydrophobic core of MDM2 R centering on I440 (Fig. 1d) . Ub-UbcH5B interactions include UbcH5B's α2 contacting Ub's I44 surface and UbcH5B's active-site residues clamping Ub's C-terminal tail (Fig. 1e) . MDM2 R -Ub interactions involve MDM2's V477 and Zn 2+ -ligand H457 and Ub's L8-I36-L71 surface. Additionally, MDM2's R479, known as the 'linchpin' arginine 38 , forms hydrogen bonds with the carbonyl oxygens of UbcH5B's Q92 and Ub's R72 and the side chain of Ub's Q40 (Fig. 1f) . These interactions are similar to those observed in other RING E3-E2-Ub complexes [30] [31] [32] [33] [34] [35] [36] [37] . MDM2 also contains a short helix that precedes the RING domain, and S429 and N433 from this helix contact Ub's T9-K11 surface (Fig. 1f) .
We mutated a selection of key residues involved in the Ub-UbcH5B (N77A, D87A, S108R, N114A and D117A in UbcH5B, and I44A and L73D in Ub), MDM2 R -Ub (N433R, V477A and R479A in MDM2, and T9A, I36A and Q40R in Ub) and MDM2 R -UbcH5B (I440A in MDM2) interfaces and performed single-turnover Ub transfer to lysine. All mutants were defective in discharging UbcH5B~Ub, suggesting that the observed interactions are important for MDM2-MDMX-catalyzed Ub transfer (Fig. 1g-i and Supplementary Fig. 1a-f) . 
a r t i c l e s a r t i c l e s
Importance of MDMX C-terminal tail in the MDM2-MDMX heterodimer E3-defective mutations in the C-terminal tail of MDM2 can be reactivated by MDMX 19, 20, 39 . Our structure shows that the last three residues of MDMX (F488, I489 and A490) play a crucial role in stabilizing the closed UbcH5B-Ub conformation. F488 packs against Ub's G35 surface, and A490 is completely buried within the MDM2 R -Ub interface, supporting Ub binding (Fig. 2a) . This binding mode suggests that MDMX's C terminus cannot accommodate extra residues. Furthermore, the structure shows that MDM2's C-terminal tail does not contact UbcH5B-Ub.
To assess the importance of MDMX's C terminus, we mutated F488 to histidine and alanine and found that both mutants were defective in discharging UbcH5B~Ub (Fig. 2b,c and Supplementary  Fig. 1g,h ). Addition of a hexahistidine tag (His-tag) to MDMX's C terminus also hindered discharge of UbcH5B~Ub ( Fig. 2d and Supplementary Fig. 1i,j) . However, alteration of the corresponding C-terminal residue in MDM2, Y489, to histidine or alanine or addition of a His-tag to MDM2's C terminus had a minimal effect (Fig. 2b-d and Supplementary Fig. 1g-j) . Therefore, the length of MDMX's C terminus impacts E2~Ub recruitment by the MDM2-MDMX heterodimer. MDMX's F488-Ub interaction is conserved in homodimeric RING E3s such as RNF4 and BIRC7 (refs. 31-33) , but in these examples, the C terminus is only partially buried, and introducing exogenous C-terminal residues minimally affects activity 40 .
A model for the MDM2 homodimer bound to E2~Ub
Given that MDMX only contributes to the tail-Ub interaction, we reasoned that MDM2's C terminus could fulfill the same role in the MDM2 homodimer. Indeed, substituting MDMX's C-terminal F488-I489-A490 with MDM2's C-terminal Y489-F490-P491 marginally improved MDM2-MDMX's activity ( Fig. 2c and Supplementary  Fig. 1g,h) , suggesting that the MDM2 homodimer likely uses a similar mechanism to the MDM2-MDMX heterodimer in activating E2~Ub. Because MDM2 and MDMX RING-domain structures are similar (r.m.s. deviation of 0.44 Å for Cα atoms), and the NMR structure of MDM2 RH (ref. 29 ) is similar to MDM2 R -MDMX R (r.m.s. deviation of 1.47 Å for Cα atoms), we generated a model of MDM2 RH bound to UbcH5B-Ub by superimposition of MDM2 R -UbcH5B-Ub from our structure onto MDMX R in the MDM2 R -MDMX R -UbcH5B-Ub structure (Fig. 3a,b) . In this model, each MDM2 RING domain To validate this model, we mutated a selection of key residues in the Ub-UbcH5B (UbcH5B S108R and Ub I44A), MDM2 R -Ub (MDM2 R479A) and Ub-MDM2 tail (MDM2 Y489A) binding interfaces and performed a UbcH5B~Ub discharge assay catalyzed by the MDM2 homodimer. All mutants were defective in discharging UbcH5B~Ub. Moreover, addition of a C-terminal His-tag reduced activity ( Fig. 3c and Supplementary Fig. 1k,l) . Thus, the MDM2 homodimer uses a similar mechanism to the MDM2-MDMX heterodimer in activating E2~Ub for catalysis.
MDM2 homodimer exhibits higher intrinsic ligase activity
The structure of the MDM2 R -MDMX R -UbcH5B-Ub complex shows that the MDM2-MDMX heterodimer can only recruit one molecule of UbcH5B-Ub at a time, whereas the model of the MDM2 RHUbcH5B-Ub complex suggests that the MDM2 homodimer can bind two molecules of UbcH5B-Ub and perhaps enable transfer of two Ub molecules simultaneously. To investigate MDM2 RH and MDM2 R -MDMX R Ub transfer mechanisms, we compared their rates of UbcH5B~Ub discharge. Because the MDM2 RING domain is known to form large oligomers and dimers during expression and purification from Escherichia coli 20 , we developed a protocol to purify the dimeric fraction of the MDM2 RING domain and then performed a UbcH5B~Ub discharge assay using fluorescently labeled Ub for quantification. At the same E3 concentration, MDM2 RH discharged UbcH5B~Ub at a faster rate than did MDM2 R -MDMX R . When the concentration of MDM2 RH concentration was halved, it displayed a rate of UbcH5B~Ub discharge similar to that of MDM2 R -MDMX R (Fig. 3d,e) . Thus, MDM2 RH displayed a two-fold higher discharge rate as compared with MDM2 R -MDMX R .
Engineering MDM2 RING domain lacking ligase activity
Most studies of MDM2's ligase-independent regulation of p53 have been based on MDM2 C464A (or C462A in mouse), a mutant that disrupts the Zn 2+ coordination 18, [41] [42] [43] . This mutation has severe consequences on the RING-domain fold and therefore the ability to homo-or heterodimerize. We sought to design an MDM2 RING mutant that abrogates the ligase activity while maintaining the RINGdomain fold to study the ligase-independent function of MDM2. Our structure and model suggest that disrupting the MDM2 RUbcH5B, MDM2 R -Ub or MDM2 tail-Ub interactions could hamper the ligase activity. Given that MDM2-tail mutants can be reactivated by MDMX 19, 20 , we focused on the MDM2 R -UbcH5B and MDM2 RUb interfaces, specifically MDM2 I440 and R479, because I440 plays the central role in E2 binding 44 , and R479 helps stabilize the closed E2~Ub conformation. The corresponding residue to I440 in BRCA1, I26, has been mutated to alanine, resulting in defective activity in vitro 45, 46 .
We mutated MDM2 I440 and R479 to several different amino acid residues (I440E, I440A, I440D, I440Y, I440R, I440K, R479A, R479P, R479I, R479G, R479F and R479K). The basic and acidic residues were expected to severely impact MDM2 R -UbcH5B hydrophobic interactions, whereas residues with no or short side chains should not support interactions initiated by the linchpin arginine. In vitro UbcH5B~Ub discharge and UbcH5B-Ub binding assays showed that all MDM2 mutants were defective in discharging UbcH5B~Ub compared to the wild-type MDM2 (Supplementary Fig. 2a ). Most I440 variants had no measurable UbcH5B-Ub binding affinity except I440Y, which displayed ~60-fold weaker affinity than that of wild-type MDM2 (Supplementary Table 1 and Supplementary Fig. 3a ). All R479 variants bound UbcH5B-Ub with weaker affinities than that of wild-type MDM2, and the R479P mutant displayed no measurable binding affinity (Supplementary Table 1 a r t i c l e s . Consistent with UbcH5B-Ub binding properties, MDM2 mutants that exhibited no measurable UbcH5B-Ub binding affinity were severely compromised in their p53 ubiquitination activity in cells, with MDM2 I440K, I440E and R479P mutants showing basal p53 ubiquitination levels, similar to the empty vector (EV), and MDM2 I440A, I440R and I440D displaying trace p53 ubiquitination activity (Fig. 4a,b) .
On the basis of these results, MDM2 I440K, I440E and R479P were selected for subsequent analyses. To verify that these mutations do not have an impact on MDM2 homo-or heterodimerization, we performed pull-down experiments in vitro. All GST-tagged MDM2 variants were able to pull down their corresponding His-tagged MDM2 and MDMX variants, suggesting that these mutants are competent in forming MDM2 homodimers and MDM2-MDMX heterodimers ( Supplementary Fig. 2b,c) .
Immunoprecipitation results showed that all of the I440 and R479 mutants retained the ability to interact with MDMX in cells (Fig. 4c) , while the negative-control MDM2 C464A did not show any interaction. These results were confirmed by showing that wild-type MDM2, I440K and I440E mutants could interact with and import MDMX into the nucleus (Fig. 4d) , while C464A did not relocalize MDMX. As expected, all mutants, including the C464A mutant, interacted with p53 ( Fig. 4e) , showing that neither an intact RING domain nor the ability of MDM2 to interact with the E2~Ub complex is required for the N terminus of MDM2 to bind to p53. Furthermore, addition of MDMX did not complement the loss of activity in MDM2 I440K or I440E mutants, whereas the defective MDM2-Y489D-tail-Ub interaction was restored with MDMX's tail in the heterodimer ( Fig. 4f and  Supplementary Fig. 2d) . Together, these results show that MDM2 I440K, I440E and R479P retain the RING-domain fold to form homoand heterodimers with MDMX but cannot interact with E2~Ub to catalyze ubiquitination.
MDMX RING domain is not optimized for E2~Ub activation
To understand the basis for the lack of activity in MDMX, we superimposed the structure of MDMX R onto MDM2 R in our MDM2 R -MDMX R -UbcH5B-Ub structure to generate a model of the MDMX R -UbcH5B-Ub complex. The model showed that MDMX R harbors residues that are less optimal in UbcH5B and Ub binding compared to those of MDM2 R (Fig. 5a,b) . Strikingly, MDMX R lacks the linchpin arginine and instead contains K478, which cannot initiate the same hydrogen-bond network as MDM2's R479. Furthermore, the MDMX R -MDMX R dimerization interface is suboptimal; the two MDMX R N448 side chains at this interface potentially clash or create an electrostatic repulsion (Fig. 5c ). MDM2 contains a C449 at this position that does not clash with C449 in the MDM2 homodimer model or MDMX's N448 in the MDM2-MDMX heterodimer (Fig. 5d,e) .
We wondered whether substituting N448C and K478R could reactivate MDMX's ligase activity. A similar MDMX mutant harboring N448C with residues 465-480 replaced with the MDM2 sequence was previously shown to promote p53 ubiquitination and degradation in cells 13 . MDMX displayed no activity under the reaction conditions a r t i c l e s of our UbcH5B~Ub discharge assay. MDMX N448C showed marginal activity, while MDMX K478R showed greatly improved activity. The MDMX N448C K478R mutant further enhanced the ligase activity (Fig. 5f) . To assess whether these MDMX variants are active in cells, we performed p53 ubiquitination assays by transfecting p53, full-length MDMX variants and His-Ub into U2OS cells. MDMX N448C and MDMX K478R exhibited no appreciable activity, while MDMX N448C K478R displayed modest p53 ubiquitination activity compared to full-length MDM2. Remarkably, when we generated an MDM2-MDMX chimera by replacing MDM2's RING domain with MDMX's RING domain (1-421: MDM2, 422-490: MDMX, "MDM2_ XRING") to avoid the complications of the lack of nuclear localization signal and nuclear export signal and a shorter acidic domain in MDMX, the N448C K478R mutant exhibited p53 ubiquitination activity similar to that of wild-type MDM2 (Fig. 5g) . Based on the model of active E3 dimers, the MDM2 I440 and R479 mutants, which have lost the ability to bind E2~Ub, may regain E3 activity by forming a dimer with a binding partner, such as MDMX or other MDM2 proteins, that retains the ability to bind to the E2~Ub complex. To test this hypothesis, MDMX K478R (not chimera) was coexpressed with MDM2 I440 mutants. All mutants were reactivated by MDMX K478R but not by wild-type MDMX (Fig. 5h) , and binding analysis showed that MDMX K478R has acquired the ability to interact with the UbcH5B-Ub complex (Supplementary Fig. 3b) . The ability of MDMX K478R to bind E2~Ub and dimerize with MDM2 I440 mutants allows it to ubiquitinate p53 (Fig. 5i) . Together, these results showed that the MDMX RING-domain sequence is not optimized for E2~Ub activation and highlighted the importance of the linchpin arginine in regulating ligase activity. Moreover, these results are consistent with earlier findings that demonstrated the requirement of the MDM2 acidic domain in promoting p53 ubiquitination and degradation in cells [47] [48] [49] . (Fig. 4f) because neither MDM2 I440 mutants nor wild-type MDMX recruit the UbcH5B-Ub complex ( Supplementary Fig. 3 ). However, these mutants can be reactivated by MDMX K478R that binds the UbcH5B-Ub complex ( Fig. 6h and Supplementary Fig. 3 ). Red cross indicates the point of mutation. Uncropped gel and blot images are shown in Supplementary Data Set 1.
a r t i c l e s
MDM2 I440 or R479 mutants limit p53 activity
To assess the effect of the MDM2 mutations on endogenous p53, we generated U2OS cells that were conditionally depleted of p53 through the use of a doxycycline-inducible shRNA, then removed endogenous MDM2 from these cells by CRISPR-Cas9 followed by stable re-expression of various MDM2 mutants ( Supplementary Fig. 4a-c) . Removal of doxycycline then allowed for the re-expression of endogenous p53. Expression of wild-type MDM2 in this system resulted in a clear degradation of p53 compared to EV transfected cells, while, as expected, the C464A, I440K, I440E and R479P mutants failed to degrade p53 (Fig. 6a,b) . Notably, however, despite failing to target p53 for degradation, the expression of the I440 or R479 mutants resulted in a significantly lower activation of p53 target genes, including p21, PIG3 and TIGAR, than was seen in cells expressing the MDM2 C464A mutant (Figs. 6a,b and 7a and Supplementary Fig. 5 ).
Chromatin immunoprecipitation (ChIP) assays to look for MDM2 at the p21 promoter showed that although wild-type MDM2 expression reduced the overall amount of p53 protein, the ratio of p53 to MDM2 at the p21 promoter suggested that low levels of both proteins were present. By contrast, although MDM2 C464A retained the ability to interact with p53 when co-precipitated in solution (Fig. 4e) , this interaction was not maintained at the p21 promoter, explaining why MDM2 C464A cannot efficiently limit p53 activity. Interestingly, the I440 and R479 mutants were all found at the p21 promoter with p53 (Fig. 6c,d) , suggesting that their ability to limit p53's transcriptional activity reflects a direct perturbation of the formation of an active transcriptional complex at the promoter. In terms of proliferation, in the absence of p53 (with doxycycline) all of the cell lines grew at the same rate (Fig. 6e) . However, following reintroduction of endogenous p53, control cells (lacking MDM2) stopped growing, whereas cells expressing wild-type MDM2 continued to proliferate (Fig. 6e) . Importantly, despite their not targeting p53 for degradation, the ability of the MDM2 I440 or R479 mutants to restrain p53 activity was sufficient to allow proliferation of these cells (Fig. 6e) .
Next, we monitored the response of cells expressing the I440 or R479 MDM2 mutants to stress signals that lead to the dissociation of the p53-MDM2 interaction. Low levels of actinomycin D inhibit MDM2 by disrupting nucleoli and releasing ribosomal proteins that bind and inhibit MDM2 (refs. 50,51); thus, we used a higher dose (10 nM) of actinomycin D, which leads to the phosphorylation of N-terminal residues of p53 and loss of MDM2 binding 52, 53 ( Supplementary Fig. 4d ). Although the expression of the MDM2 I440 or R479 mutants restrained the activation of p53 target genes similarly to the expression of wild-type MDM2, cells expressing MDM2 I440 or R479 mutants responded more robustly to an 18-h treatment with actinomycin D (Fig. 7a-c and Supplementary Fig. 6 ), leading to a higher expression of p53 target genes in cells expressing mutant as compared to wild-type MDM2. As expected, actinomycin D increased p53 levels in cells expressing wild-type MDM2 but did not affect the higher p53 levels in cells expressing the E3-defective MDM2 I440, R479 or C464A mutants (Fig. 7b,c) . As previously reported 54, 55 , stabilization of p53 was accompanied by a decrease in MDMX levels, a response that was evident only in cells expressing wild-type MDM2 but not the E3-defective mutant. A time course of the response showed that the lack of requirement to stabilize p53 in cells expressing MDM2 I440 or R479 correlated with a more rapid increase in expression of p21 and PIG3 after actinomycin D treatment compared a r t i c l e s to a more gradual increase seen in cells expressing wild-type MDM2 (Fig. 7b,c) . Similar results were obtained in cells treated with two other inhibitors of the p53-MDM2 interaction, nutlin ( Supplementary  Fig. 6b ) and doxorubicin (Supplementary Fig. 6c ). Consistent with these results, cells expressing MDM2 I440 or R479 mutants showed a more rapid attenuation of cell growth in response to actinomycin D than cells with wild-type MDM2 (Fig. 7d,e) . Therefore, although these MDM2 mutants are unable to control p53 levels, they can still repress p53 activity. Moreover, the high levels of p53 in cells expressing these MDM2 mutants can be more rapidly activated in response to stress than p53 in cells with wild-type MDM2 (which degrades p53), where the p53 protein must still accumulate.
DISCUSSION
The ability of MDMX to interact with MDM2 through the RING domain has been described to both inhibit or enhance MDM2 E3-ligase activity 10, 56, 57 . Our present work provides structural and mechanistic insights into how the MDM2 homodimer and MDM2-MDMX heterodimer bind and activate E2~Ub for transfer. Both complexes utilize a mechanism similar to those previously reported for other RING E3s [30] [31] [32] [33] [34] [35] [36] [37] [38] 58 , whereby MDM2 RING-E2, MDM2-Ub and Ub-E2 interactions restrain E2~Ub into a closed conformation that optimally positions the E2~Ub thioester bond for transfer. Complementing previous studies 19, 20, 39 , we show that the C-terminal tails of MDM2 and MDMX in the MDM2 homodimer and MDM2-MDMX heterodimer, a r t i c l e s respectively, and their lengths, play a critical role in supporting Ub binding. In vivo, a C-terminal tail mutant of MDM2 was able to control p53 to allow normal development through a mechanism that required MDMX heterodimerization 21 . Surprisingly, although this complex retains E3 activity, p53 protein accumulated in some tissues and cells from these mice, suggesting that degradation was compromised. While the mechanism whereby this C-terminal mutant controls p53 under these conditions remains unclear, these results are consistent with our observations that MDM2 shows E3-independent functions in regulating p53.
Our data indicate that despite their apparent structural similarity, the MDM2 homodimer and MDM2-MDMX heterodimer have differing abilities to transfer Ub due to their abilities to interact with E2~Ub complexes, and that the MDM2 homodimer exhibits higher intrinsic ligase activity than the MDM2-MDMX heterodimer. This can be attributed to the inability of MDMX to recruit E2~Ub, thereby halving the amount of E2~Ub recruited by a heterodimer (compared to an MDM2 homodimer), or the MDM2 RING domain exhibiting a higher turnover rate in the context of the MDM2 homodimer. However, the experiments performed here are based on the RING domain, and the regulation of these complexes by posttranslational modification 59 , other domains 9, 60 or other protein partners could favor the activity of the full-length MDM2-MDMX heterodimer.
Consistent with an earlier study showing that replacement of MDMX's N448 and residues 465-480 with MDM2's sequences was able to stimulate MDMX's ligase activity 13 , we found that substituting MDMX's N448 and K478 to cysteine and arginine, respectively, were sufficient to unmask its ligase activity. The N448C mutation enables RING-domain homodimerization, thereby allowing MDMX-tail-Ub interaction, whereas K478R presumably stabilizes the closed E2~Ub conformation, as observed in our structure. These results further underscore the importance of C-terminal-tail-Ub interaction and the linchpin arginine in modulating the ligase activity.
Prior studies have used the MDM2 C464A mutant to assess MDM2's ligase-independent functions in regulating p53, but C464A also abolishes the RING-domain fold. It is therefore not clear whether failure of this mutant (or the mouse equivalent) to control p53 (ref. 18 ) reflects a loss of E3 function, a loss of dimerization or a failure to bind to p53 at promoters. We show that MDM2 I440K, I440E and R479P lack interaction with E2~Ub complexes and abolish MDM2's E3 activity but retain its ability to interact with p53 and to homodimerize or heterodimerize (with MDMX), suggesting they retain an intact RINGdomain fold. These mutants can be localized on the p21 promoter (via p53) and efficiently reduce p53's transcriptional activity, allowing proliferation but rendering cells hypersensitive to stress. Interestingly, MDM2 C464A also retains some effect on cell growth and modestly limits the induction of p53 target genes, including p21 (Fig. 6a,b) , potentially reflecting the ability of this mutant to bind p53 in solution. A summary of the activity of these MDM2 mutants is available in Supplementary Table 2.
Finally, it is possible that targeting the catalytic activity of MDM2 to reactivate wild-type p53 in tumors (which have elevated levels of stress) could open a therapeutic window by avoiding the deleterious on-target side effects of completely disrupting the MDM2-p53 interaction in normal tissue. Previous work has described small-molecule inhibitors of MDM2 that bind to the RING domain, inhibiting E3 activity and stabilizing p53 (ref. 61) , suggesting that such an approach is feasible.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
ONLINE METHODS
Protein preparation. All constructs were generated by standard PCR-ligation techniques. All proteins are human unless otherwise specified and were expressed in BL21 (DE3) cells or BL21 (DE3) RIL (Stratagene). To generate MDM2 R -MDMX R (MDM2 428-C and MDMX 427-C) for crystallization and assays, MDM2 R and MDMX R were cloned into the first and second multiple cloning site of a bicistronic vector or RSF_Duet (Novagen), respectively, where MDM2 R contains an N-terminal 6×His-tag followed by a TEV protease cleavage site. 6×His-MDM2 R -MDMX R was purified by Ni-NTA affinity, followed by cation exchange and size-exclusion chromatography. All MDM2 R -MDMX R variants were purified in the same manner (Supplementary Fig. 7a) . To generate C-terminal 6×His-tagged MDM2 R -MDMX R variants, MDM2 R and MDMX R variants were cloned into pGEX4T1 (GE Healthcare) containing an N-terminal GST-tag and RSF_Duet containing an N-terminal His-tag. MDM2 R -MDMX R variants were formed by co-expressing GST-MDM2 R with His-MDMX R variants or GST-MDMX R with His-MDM2 R variants and subsequently purified by Ni-NTA affinity chromatography, followed by glutathione affinity chromatography (Supplementary Fig. 7b ). For MDMX reactivation and binding assays, MDMX R variants were cloned into pGEX4T1 containing an N-terminal GST-tag followed by a TEV protease cleavage site. MDMX R variants were purified by glutathione affinity chromatography for binding analyses or released from the beads by incubation with TEV overnight, followed by cation-exchange chromatography for reactivation assays (Supplementary Fig. 7c ). For binding analyses and assays, MDM2 398-C variants were cloned into pGEX4T1 and purified by glutathione affinity chromatography (Supplementary Fig. 7d,e) . MDMX R variants (10 µM; 100 µl) were loaded onto Superdex 75 10/300 to assess their dimerization state (Supplementary Fig. 7f) . To obtain pure MDM2 RH for assay, MDM2 R was cloned into pGEX4T1 containing an N-terminal 6×His-GST-tag followed by a TEV protease cleavage site, expressed in 36 L of LB broth, purified by glutathione affinity chromatography and subsequently buffer exchanged into 50-mM TrisHCl, pH 7.6, 0.4 M NaCl, 5%(v/v) glycerol and 1-mM DTT. 6×His-GST tag was removed by incubation with TEV followed by Ni-NTA pass-back. The cleaved MDM2 R was further purified by HiLoad 26/600 Superdex 200 chromatography ( Supplementary Fig. 7c,g ). For ubiquitination assays, Arabidopsis thaliana Uba1, UbcH5B variants and Ub variants were prepared as described previously 34 . UbcH5B S22R -Ub and UbcH5B-Ub used for crystallization and binding analyses, respectively, were prepared as previously described 34 . To generate fluorescently labeled Ub, an MHHHHHHCG sequence was inserted at the N terminus of Ub and purified by Ni-NTA affinity and size-exclusion chromatography in PBS buffer, pH 6.6. The protein was labeled by incubation with IRDye 800CW Maleimide (LI-COR) at a molar ratio of 4:1 (protein:dye) for 2 h at 22 °C in the dark and subsequently buffer exchanged into 25-mM HEPES, pH 7.0 and 150-mM NaCl using a Zeba Spin Desalting Column (Thermo Fisher) to remove excess dye. Protein concentrations were determined by Bio-RAD protein assay using BSA as a standard, and Ub concentration was determined as previously described 34 . All MDM2, MDMX and MDM2-MDMX variants were stored in 25-mM Tris-HCl, pH 7.6, 0.4-M NaCl and 1-mM DTT, and other proteins were stored in 25-mM Tris-HCl, pH 7.6, 0.15-M NaCl and 1-mM DTT. All plasmids generated for protein expression were described in Supplementary Table 4. Crystallization. MDM2 R -MDMX R -UbcH5B-Ub complex was obtained by mixing 6×His-MDM2 R -MDMX R (6.6 mg/ml) and UbcH5B S22R -Ub (20 mg/ml) at a 1:1 molar ratio. Crystals were grown at 19 °C by microseeding using the hanging-drop vapor diffusion method by mixing the complex with an equal volume of reservoir solution containing 0.1-M Tris-HCl, pH 8. Structural determination. The data were integrated with automated XDS 62 and scaled using the CCP4 program suite 63 . Initial phases were obtained by molecular replacement with PHASER 64 using UbcH5B and Ub from PDB 3ZNI 30 and MDM2 R -MDMX R from PDB 3VJF 28 as the search models. Two copies of MDM2 R -MDMX R -UbcH5B-Ub complex were found in the asymmetric unit. The model was built in COOT 65 and refined using PHENIX 66 . The complex was refined to a resolution of 2.16 Å and the final model contained two copies of UbcH5B (Chains A and E residues 2-147), Ub (Chains B and F residues 1-76), MDM2 R (Chains C and G residues 428-491) and MDMX R (Chains D and H residues 427-490). Residues with no observable side chain electron density were built as alanine stub. Details of the refinement statistics are shown in Table 1 . All figure models were generated using PYMOL (Schrödinger).
Surface Plasmon resonance (SPR) analyses. All SPR experiments were performed at 25 °C on a Biacore T200 with a CM-5 chip (GE Healthcare). GST-MDM2 398-C and GST-MDMX R variants were coupled to CM-5 chips as described previously 34 . For GST-MDM2 398-C variants, UbcH5B-Ub variants were serially diluted in running buffer containing 25-mM Tris-HCl, pH 7.6, 150-mM NaCl, 0.1-mg/ml BSA, 1-mM DTT, 0.005% (v/v) Tween-20 and 300-µM Ub∆GG. Ub∆GG was included to saturate UbcH5B's backside for optimal RING E3-UbcH5B-Ub interaction as previously described 34 . For GST-MDMX R variants, UbcH5B-Ub variants were serially diluted in running buffer containing 25-mM Tris-HCl, pH 7.6, 150-mM NaCl, 0.1-mg/ml BSA, 1-mM DTT and 0.005% (v/v) Tween-20. Binding was measured at indicated concentration ranges in Supplementary Figure 3 in duplicate. Data reported are the difference in SPR signal between GST-MDM2 398-C or GST-MDMX R variants and GST alone. The data were analyzed by steady-state affinity analysis using Biacore T200 BIAevaluation software (GE Healthcare) and Scrubber2 (BioLogic Software).
Single-turnover lysine discharge assays. UbcH5B variants (7-10 µM) were charged with Ub variants (20-50 µM) in buffer containing 50-mM Tris-HCl, pH 7.6, 50-mM NaCl, 0.5-µM A. thaliana UBA1 and 1-mg/ml BSA for 20 min at 23 °C, and charging was stopped by incubating the reaction with 0.01 U/ml apyrase (Sigma) and 30-mM EDTA for 2-3 min at 23 °C as previously described 34 . The lysine-discharge reactions were then initiated by adding a mixture containing 50-mM Tris-HCl, pH 7.6, 50-mM NaCl, 1 mg/ml BSA, L-lysine (150 mM or 50 mM for Supplementary Fig. 1 ) and E3 variants (as indicated or 0.3 µM in Figs. 1g-i, 2c,d and 3c and Supplementary Fig. 2d ; 0.8 µM in Supplementary  Fig. 1a,c,g,i, k; 0.6 µM in Supplementary Fig. 1e ; and 0.25 µM in Supplementary  Fig. 2a) . Final concentrations are in parenthesis. Reactions were quenched with SDS loading buffer at the indicated times, resolved by SDS-PAGE and visualized by staining with InstantBlue (Expedeon). For quantification in Supplementary  Figure 1 , the reactions were performed in triplicate. LI-COR Odyssey scanner was used to analyze the stained gels and bands were quantified by using Image Studio Lite software (LI-COR Biosciences). The fraction of UbcH5B~Ub left was plotted on a bar graph. In Figure 3d , Fluorescently labeled Ub was used instead of Ub, and visualization was performed using a LI-COR Odyssey scanner before staining with InstantBlue. The fluorescently labeled UbcH5B~Ub band was quantified by using Image Studio Lite software (LI-COR Biosciences).
In vitro pull-down experiments. GST-MDM2 398-C variants were co-expressed with the respective His-MDM2 398-C variants or His-MDMX 383-C as shown in Supplementary Figure 2b ,c. Cells were harvested, lysed and centrifuge. Lysates were applied onto 400 µl of Ni-NTA beads, washed with 25-mM Tris-HCl, pH 7.6, 0.2-M NaCl, 20-mM imidazole and 5-mM β-mercaptoethanol and eluted with 25-mM Tris-HCl, pH 7.6, 0.2-M NaCl, 200-mM imidazole and 5-mM β-mercaptoethanol. The eluted product was then applied onto 400 µl of Glutathione Sepharose beads, washed with 50-mM Tris-HCl, pH 7.6, 0.2-M NaCl, 5-mM DTT and eluted with 50-mM Tris-HCl, pH 7.6, 0.2-M NaCl, 5-mM DTT and 10-mM glutathione. 3 µg of eluted product was then resolved on the SDS-PAGE. For control experiments, GST-MDM2 398-C, His-MDM2 398-C and His-MDMX 383-C were expressed individually. The lysates were divided in half, applied onto 400 µl of Ni-NTA or Glutathione Sepharose beads, washed and eluted with buffer as above. 3 µg of eluted product or equal volume (for proteins that do not bind the beads but eluted with the same volume) was then resolved on the SDS-PAGE and visualized by staining with InstantBlue.
Cell culture and generation of tetracycline-inducible p53 knockdown-MDM2 knockout cells. Human osteosarcoma U2OS or human embryonic kidney HEK293 cells were obtained from ATCC and were cultured in DMEM supplemented with 10% FBS and 2-mM L-Glutamine. All cell lines were mycoplasma negative and were authenticated by STR multiplex assay.
In the experiments showed in Figures 6 and 7 and Supplementary Figures 4-6 , tetracycline-inducible p53-knockdown MDM2-knockout cells were used. U2OS cells were infected with pLKO tet-on shRNA targeting p53 and selected
